Home » Stocks » ASND

Ascendis Pharma A/S (ASND)

Stock Price: $166.51 USD 1.59 (0.96%)
Updated December 4, 12:01 PM EST - Market open

ASND Stock Price Chart

Key Info

Market Cap 8.89B
Revenue (ttm) 10.63M
Net Income (ttm) -428.99M
Shares Out 52.72M
EPS (ttm) -3.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $166.51
Previous Close $164.92
Change ($) 1.59
Change (%) 0.96%
Day's Open 166.32
Day's Range 164.31 - 166.62
Day's Volume 18,694
52-Week Range 97.01 - 174.79

ASND Stock News

GlobeNewsWire - 1 week ago

COPENHAGEN, Denmark, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product can...

Seeking Alpha - 2 weeks ago

Ascendis has a PDUFA date of June 25, 2021 for its lead indication. However, what makes this pre-market stage company so valuable is its TransCon platform.

Seeking Alpha - 3 weeks ago

Ascendis Pharma's (ASND) CEO Jan Mikkelsen on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 weeks ago

– Event will provide an overview of how A s cendis is applying its TransCon ™ technology platform and its unique algorithm for product innovation to the therapeutic area of o ncology –

Benzinga - 3 weeks ago

Shares of Ascendis Pharma (NASDAQ:ASND) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 365.52% over the past year to ($...

GlobeNewsWire - 3 weeks ago

– European Medicines Agency (EMA) validated the Marketing Authorisation Application (MAA)  f or TransCon TM hGH (lonapegsomatropin) in pediatric growth hormone deficiency (GHD) –

Zacks Investment Research - 3 weeks ago

Ascendis (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

GlobeNewsWire - 1 month ago

COPENHAGEN, Denmark, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medi...

GlobeNewsWire - 1 month ago

COPENHAGEN, Denmark, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medi...

GlobeNewsWire - 1 month ago

COPENHAGEN, Denmark, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medic...

GlobeNewsWire - 1 month ago

COPENHAGEN, Denmark, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medi...

Zacks Investment Research - 2 months ago

Ascendis Pharma (ASND) reports encouraging preliminary data on its hypoparathyroidism candidate, TransCon PTH. A late-stage study is anticipated to begin soon.

GlobeNewsWire - 2 months ago

- Six-month data from PaTH Forward open-label extension support potential use of  TransCon PTH as a hormone replacement therapy for adult hypoparathyroidism –

GlobeNewsWire - 2 months ago

COPENHAGEN, Denmark, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet me...

GlobeNewsWire - 2 months ago

– Introduces #Together4Growth to increase awareness of children’s growth disorders, including a four-question Growth Quiz to help parents identify signs and symptoms –

GlobeNewsWire - 2 months ago

COPENHAGEN, Denmark, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet m...

GlobeNewsWire - 2 months ago

COPENHAGEN, Denmark, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet me...

Investors Business Daily - 2 months ago

Ascendis Pharma sees its Relative Strength Rating reach the 80-plus level. The post Stocks Showing Rising Market Leadership: Ascendis Pharma Earns 82 RS Rating appeared first on Investor's Bus...

GlobeNewsWire - 2 months ago

COPENHAGEN, Denmark, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that uses its novel TransCon technologies to address unmet medical nee...

GlobeNewsWire - 3 months ago

– Prescription Drug User Fee Act (PDUFA) target action date of June 25, 2021 –

GlobeNewsWire - 3 months ago

COPENHAGEN, Denmark, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet me...

GlobeNewsWire - 3 months ago

COPENHAGEN, Denmark, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet m...

Seeking Alpha - 3 months ago

Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q2 2020 Results - Earnings Call Transcript

Benzinga - 3 months ago

Shares of Ascendis Pharma (NASDAQ:ASND) were unchanged after the company reported Q2 results.

GlobeNewsWire - 3 months ago

– U.S. Biologics License Application for TransCon ™ hGH submitted to U.S. Food and Drug Administration for pediatric growth hormone deficiency –

GlobeNewsWire - 3 months ago

COPENHAGEN, Denmark, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet me...

Zacks Investment Research - 3 months ago

Ascendis' (ASND) TransCon CNP receives an Orphan Drug tag in Europe for the treatment of achondroplasia, the most common type of dwarfism.

GlobeNewsWire - 3 months ago

COPENHAGEN, Denmark, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet med...

GlobeNewsWire - 4 months ago

COPENHAGEN, Denmark, July 07, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet med...

GlobeNewsWire - 4 months ago

COPENHAGEN, Denmark, July 06, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet med...

GlobeNewsWire - 4 months ago

– Supports the investigation of TransCon hGH for treatment of growth hormone deficiency in the pediatric population from 6 months to less than 18 years of age –

Zacks Investment Research - 5 months ago

Ascendis Pharma (ASND) submits BLA to the FDA for TransConhGH for the treatment of pediatric growth hormone deficiency.

GlobeNewsWire - 5 months ago

– European marketing application on track for third quarter 2020 submission – – European marketing application on track for third quarter 2020 submission –

GlobeNewsWire - 5 months ago

- In vitro data demonstrated selective binding and activation of IL-2 β/γ  receptor, associated with reduced IL-2 α   receptor binding -

Investors Business Daily - 5 months ago

When building your watchlist, focus on stocks with an 80 or higher RS Rating. Ascendis Pharma (ASND) is one stock that just reached the mark, now earning a score of 84. If it's not there alrea...

GlobeNewsWire - 5 months ago

COPENHAGEN, Denmark, June 08, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet med...

Seeking Alpha - 6 months ago

Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

COPENHAGEN, Denmark, May 11, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet med...

InvestorPlace - 6 months ago

Amid the COVID-19 pandemic, the investing pros say that it’s still possible to unmask names poised to take off on an upward trajectory.

Other stocks mentioned: ARGX, AXSM, FOLD, IOVA, NTRA, UTHR
GlobeNewsWire - 7 months ago

– PaTH Forward Trial met key objectives and showed that TransCon PTH eliminated standard of care in 82 percent of subjects within four weeks   –

GlobeNewsWire - 7 months ago

COPENHAGEN, Denmark, April 15, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet me...

Seeking Alpha - 8 months ago

Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

– On track with 2020 corporate milestones –

Zacks Investment Research - 8 months ago

Ascendis Pharma (ASND) has seen solid estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 8 months ago

Ascendis Pharma A/S (ASND) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GuruFocus - 10 months ago

The Vanguard Health Care Fund (Trades, Portfolio) released its fourth-quarter 2019 portfolio late last week, listing four new holdings.

Other stocks mentioned: RETA, SRPT
GlobeNewsWire - 10 months ago

COPENHAGEN, Denmark, Jan. 12, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address signific...

Seeking Alpha - 11 months ago

Ascendis Pharma: Technology To Remove Stringency Of Dosage Regimen At Heart Of Success

Zacks Investment Research - 1 year ago

Top Ranked Momentum Stocks to Buy for November 21st

Other stocks mentioned: AMAT, APYX
Seeking Alpha - 1 year ago

Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q3 2019 Results - Earnings Call Transcript

About ASND

Ascendis Pharma A/S, a biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone which is in Phase II clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide which is in Phase II clinical for the treatment of achondroplasia. It is also developing preclinical studies in the field of oncology... [Read more...]

Industry
Biotechnology
IPO Date
Jan 28, 2015
CEO
Jan Moeller Mikkelsen
Employees
330
Stock Exchange
NASDAQ
Ticker Symbol
ASND
Full Company Profile

Financial Performance

In 2019, ASND's revenue was 13.38 million, an increase of 26.41% compared to the previous year's 10.58 million. Losses were -218.02 million, 67.6% more than in 2018.

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for ASND stock is "Strong Buy." The 12-month stock price forecast is 192.05, which is an increase of 15.34% from the latest price.

Price Target
$192.05
(15.34% upside)
Analyst Consensus: Strong Buy